DRAXIMAGE(R)’s generic Sestamibi Approved for launch in USA
Exclusive distribution agreement in place with GE Healthcare
DRAXIMAGE(R) Sestamibi, is a generic kit used in the preparation of Technetium (Tc-99m) Sestamibi injection – a diagnostic cardiac imaging agent used in Myocardial Perfusion Imaging (MPI), to evaluate the flow of blood to the heart. The MPI market size is currently estimated at
Jubilant, through its subsidiary in the US, has an exclusive distribution agreement with GE Healthcare to distribute and sell DRAXIMAGE(R)’s generic Sestamibi through GE Healthcare’s nuclear pharmacy network in the US.
Commenting on the development,
The DRAXIMAGE(R)’s generic Sestamibi USFDA approval is a significant milestone for the Company’s radiopharma business. Along with the earlier approvals in
GE Healthcare is regarded as a strong player in the nuclear medicine market. It has a very strong network of nuclear pharmacies across the US with a considerable market share in the MPI segment.
DRAXIMAGE(R) Sestamibi is the only generic Tc-99m for MPI, to be marketed by GE, thus complementing GE’s product and service offerings to their customers. The initial term of the distribution agreement is for a minimum of three years post approvals and the product is expected to be launched shortly.
About Jubilant Organosys
Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of
For more information: visit www.jubl.com
DRAXIMAGE, develops, manufactures and markets diagnostic and therapeutic radiopharmaceuticals for the global nuclear medicine marketplace.
Products include a proprietary line of lyophilized technetium-99m kits (MAA, MDP, DTPA and Sestamibi) used in several medical imaging procedures. DRAXIMAGE is also a leading supplier of I-131 radiopharmaceuticals in
For more information: visit www.draximage.com
Cardiolite(R) is a registered trademark of Lantheus Medical Imaging
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.
SOURCE DRAXIS Specialty Pharmaceuticals Inc.